Related Experiment Videos
[Renal damage during type II cryoglobulinemia].
Frank Bridoux1, François Provôt, Ramzi Abou Ayache
1Service de néphrologie, hémodialyse et transplantation rénale, Hôpital Jean Bernard, CHU Poitiers. f.bridoux@chu-poitiers.fr
Presse Medicale (Paris, France : 1983)
|April 26, 2003
Summary
Type II cryoglobulinemia, linked to hepatitis C, frequently causes kidney damage like glomerulonephritis. Treatment involves antivirals, immunosuppressors, and managing cardiovascular issues for better outcomes.
Area of Science:
- Nephrology
- Immunology
- Hepatology
Background:
- Type II cryoglobulinemia involves monoclonal IgM rheumatoid factor against polyclonal IgG.
- It is strongly associated with chronic hepatitis C viral infection.
- Renal damage is a common systemic manifestation.
Purpose of the Study:
- To describe the characteristics of renal damage in Type II cryoglobulinemia.
- To outline current therapeutic modalities and their effectiveness.
- To emphasize the prognostic significance of cardiovascular complications.
Main Methods:
- Review of clinical manifestations and renal biopsy findings.
- Analysis of treatment strategies including antivirals, corticosteroids, and immunosuppressors.
- Evaluation of outcomes and prognostic factors.
Main Results:
- Renal damage presents as moderate renal failure, hematuria, proteinuria (<3 g/d), and hypertension.
- Severe forms include nephrotic/nephritic syndromes or multi-organ failure.
- Renal biopsy shows membranoproliferative glomerulonephritis with specific glomerular deposits and vasculitis.
- Progression to end-stage renal failure is uncommon.
Conclusions:
- Type II cryoglobulinemia-associated glomerulonephritis requires a multidisciplinary approach.
- Antiviral therapy combined with immunosuppression shows partial efficacy.
- Management of cardiovascular complications is crucial for patient survival.